999 related articles for article (PubMed ID: 29067469)
1. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
Xia Y; He Z; Liu B; Wang P; Chen Y
Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
4. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
5. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells.
Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
Oncol Rep; 2020 Sep; 44(3):1025-1036. PubMed ID: 32705261
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
Wang W; Dong ML; Zhang W; Liu T
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373
[TBL] [Abstract][Full Text] [Related]
8. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
Shen Q; Xu Z; Xu S
Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
[TBL] [Abstract][Full Text] [Related]
9. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z
PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654
[TBL] [Abstract][Full Text] [Related]
10. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
Ju ZS; Sun B; Bao D; Zhang XF
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
[TBL] [Abstract][Full Text] [Related]
11. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA OR3A4 promotes cisplatin resistance of non-small cell lung cancer by upregulating CDK1.
Shang J; Xu YD; Zhang YY; Li M
Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4220-4225. PubMed ID: 31173293
[TBL] [Abstract][Full Text] [Related]
13. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
14. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Chen Y; Zhou H; Yang S; Su D
Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
[TBL] [Abstract][Full Text] [Related]
15. Silence of lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells.
Liu X; Huang Z; Qian W; Zhang Q; Sun J
J Cell Biochem; 2019 Jun; 120(6):9243-9249. PubMed ID: 30652341
[TBL] [Abstract][Full Text] [Related]
16. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
[TBL] [Abstract][Full Text] [Related]
17. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
Huang Q; Xing S; Peng A; Yu Z
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
19. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
20. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
